Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

MARINUS TSC [TRUSTTSC]-DB

A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) (NCT05323734)

Currently recruiting

MarkV-01

A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors (NCT05957081)

Currently recruiting

MASTERPLAN

MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (NCT04089150)

No longer recruiting

MAT

The Metformin Aneurysm Trial (MAT) (ACTRN12618001707257)

Currently recruiting

MEGA-ROX

The Mega Randomised Registry Trial Comparing Conservative vs.Liberal OXygenation Targets (Mega-ROX) (ACTRN12620000391976)

No longer recruiting

MEL-SELF

MEL-SELF: A randomised controlled trial of a patient-led surveillance compared to clinician-led surveillance in people treated for early-stage melanoma (stage 0/I/II) (ACTRN12621000176864)

Currently recruiting

MelMarT

Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randominsed control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma (ACTRN12614000667617)

Currently recruiting

MEMENTO

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging [CMR] (NCT06112743)

Currently recruiting

MHT vs SSRI

A randomised double-blinded interventional trial of estradiol and zoloft to treat menopausal depression (ACTRN12624000475549p)

Currently recruiting

MIDAS 2

A Phase III, Multicentre, Prospective, Randomised, Placebo-controlled, Double-blind, Parallel group, with an adaptive sample size re-estimation study in Stroke Survivors (ACTRN12618000602224)

Currently recruiting

MIST

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation [AP01] in Subjects with Progressive Pulmonary Fibrosis [PPF] (NCT06329401)

Currently recruiting

MK-0482-001

A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors. (NCT03918278)

No longer recruiting

MK-1022-011

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers (NCT06596694)

Currently recruiting

MK-1200-002

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors (NCT06242691)

No longer recruiting

MK-4280A-010

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)

No longer recruiting

MK-6837

A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (NCT06460961)

Currently recruiting

MK-8591B 060

Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With HIV-1 (NCT06891066)

Currently recruiting

MND-PLL001

A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo-controlled Study with an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of Subjects with Amyotrophic Lateral Sclerosis (NCT06513546)

Currently recruiting

MODUS

Multi-Organ Denervation to RedUce Sympathetic Drive, A Single Blinded, Multi-Center, Prospective Feasibility Study (MODUS Study) (ACTRN12620000412932)

Recently completed/closed

MOG001

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) (NCT05063162)

Currently recruiting
18 19 20 21 22